Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Core Insights - Achieve Life Sciences, Inc. has appointed Kristen Slaoui, Ph.D., and Nancy Phelan to its Board of Directors, bringing extensive experience in corporate strategy and commercialization to support the development of cytisinicline for smoking cessation [1][2][3] Company Overview - Achieve Life Sciences is focused on the global development and commercialization of cytisinicline, a treatment for smoking cessation and nicotine dependence [4] - The company has completed two Phase 3 studies for cytisinicline in smoking cessation and one Phase 2 study for vaping cessation, with plans to submit a new drug application in Q2 2025 [5] Industry Context - Approximately 29 million adults smoke combustible cigarettes, with tobacco use being the leading cause of preventable death, resulting in over 8 million deaths globally and nearly 500,000 in the U.S. annually [6] - There are over 11 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation [7] - Cytisinicline has been granted Breakthrough Therapy designation to address the urgent need for effective treatments in this area [7][8]